TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10357377

Group type: EXPERIMENTAL
Intervention: Highly aggressive antiretroviral therapy (HAART)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Zidovudine (ZDV) monotherapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Triple combination (ZDV, 3TC, SQV)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Quadruple combination (ZDV, 3TC, SQV, RTV)
Number of subjects: 28
Study: 7573097

Group type: EXPERIMENTAL
Intervention: Interferon-α (IFN-α) therapy at a dosage of 5 million units (MU)/m2 per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon-α (IFN-α) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Interferon-α (IFN-α) and chemotherapy
Number of subjects: 0
Study: 2149493

Group type: EXPERIMENTAL
Intervention: Teicoplanin 6 mg/kg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Teicoplanin 12 mg/kg
Number of subjects: 49
Study: 7381125

Group type: EXPERIMENTAL
Intervention: Metaproterenol 0.65 mg (3 inhalations at 10 and 20 min)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Metaproterenol 1.95 mg (single inhalation)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (3 inhalations at 10 and 20 min)
Number of subjects: 19
Study: 30859377

Group type: EXPERIMENTAL
Intervention: Biolimus A9-eluting stent (2-link BES)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Everolimus-eluting stent (3-link EES)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 226
Study: 26936898

Group type: EXPERIMENTAL
Intervention: Low carbohydrate, high fat, and protein-permitted diet
Number of subjects: 126

Group type: COMPARATOR
Intervention: Fasting for at least 12 hours
Number of subjects: 126
Study: 25655763

Group type: EXPERIMENTAL
Intervention: PDI-Couple Interview (PDI-CI) delivered by a clinical psychologist
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PDI-Couple Interview (PDI-CI)
Number of subjects: 12
Study: 23110580

Group type: EXPERIMENTAL
Intervention: 1-SEAs (Futurabond M, Clearfil S3 Bond, Optibond All-in-One)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2-ERA (Adper Single Bond 2/3M ESPE)
Number of subjects: 50
Study: 21649633

Group type: EXPERIMENTAL
Intervention: Activities adjusted to personality style of interest (PSI), n=33
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Activities adjusted to functional level and personality style of interest (FL+PSI), n=31
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Activities adjusted to functional level (FL), n=32
Number of subjects: 128

Group type: COMPARATOR
Intervention: Active control (AC), n=32
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: All treatments (FL, PSI, FL+PSI)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: One week after intervention
Number of subjects: 128
Study: 19454025

Group type: EXPERIMENTAL
Intervention: Modified houses with ceilings of papyrus mats and insecticide-treated netting (ITN)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unmodified houses (Control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Modified houses with ceilings of papyrus mats and ITN
Number of subjects: 20
Study: 18095197

Group type: EXPERIMENTAL
Intervention: 900 mg gabapentin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1200 mg gabapentin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no gabapentin)
Number of subjects: 45
Study: 14555862

Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg cumulative dose: 6.25 mg + 18.75 mg 1 h later)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 216
Study: 10866081

Group type: EXPERIMENTAL
Intervention: 12.5 micromol/kg Gd-EOB-DTPA
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 25 micromol/kg Gd-EOB-DTPA
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 50 micromol/kg Gd-EOB-DTPA
Number of subjects: 35
Study: 9199073

Group type: EXPERIMENTAL
Intervention: Continuous cryotherapy (closed system)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Intermittent cryotherapy (conventional cold packs)
Number of subjects: 312
Study: 8482064

Group type: EXPERIMENTAL
Intervention: Metadoxine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 3885033

Group type: EXPERIMENTAL
Intervention: Penicillamine (1 g per day)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Penicillamine
Number of subjects: 227
Study: 30221864

Group type: EXPERIMENTAL
Intervention: Magnesium oxide treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 29
Study: 27093773

Group type: EXPERIMENTAL
Intervention: 0.454% w/w stannous fluoride dentifrice (test dentifrice)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Marketed standard fluoride dentifrice (negative control)
Number of subjects: 351
Study: 24233343

Group type: EXPERIMENTAL
Intervention: HPV16 synthetic long-peptide vaccine (HPV16-SLP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Booster vaccination after 1 year with HPV16-SLP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22893132

Group type: EXPERIMENTAL
Intervention: High-definition colonoscopes (EC-530 and EC-590) using Flexible Spectral Imaging Color Enhancement (FICE)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Standard-definition colonoscopes (EC-530) using Flexible Spectral Imaging Color Enhancement (FICE)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: High-definition colonoscopes (EC-530 and EC-590) using White Light Imaging (WLI)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Standard-definition colonoscopes (EC-530) using White Light Imaging (WLI)
Number of subjects: 293
Study: 20825316

Group type: EXPERIMENTAL
Intervention: Gentamicin-collagen sponge
Number of subjects: 602

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 602
Study: 18432488

Group type: EXPERIMENTAL
Intervention: Study of theme-related items presented in nonword form
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Jumbled words with difficult letter rearrangements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presentation durations ranging from 110 ms to 880 ms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study conditions conducive to recoding
Number of subjects: 0
Study: 16201125

Group type: COMPARATOR
Intervention: Whipple procedure
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: PPPD
Number of subjects: 36
Study: 12907329

Group type: EXPERIMENTAL
Intervention: Propofol sedation
Number of subjects: 1370
Study: 10388649

Group type: EXPERIMENTAL
Intervention: Vaccine formulated into Iscom particles
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard influenza vaccine
Number of subjects: 100
Study: 9116931

Group type: EXPERIMENTAL
Intervention: 30 degrees right anterior oblique (RAO) projection
Number of subjects: 206

Group type: COMPARATOR
Intervention: 60 degrees left anterior oblique (LAO) projection
Number of subjects: 206
Study: 1799472

Group type: COMPARATOR
Intervention: Chlorambucil (CB; 10 mg/day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Chlorambucil (CB) plus interferon alfa‐2b (5 million units (MU)/m2 subcutaneously three times a week)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b during the induction phase
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with interferon alfa‐2b
Number of subjects: 70
Study: 6152029

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Promethazine 25 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propiomazine 25 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31931269

Group type: COMPARATOR
Intervention: Implanted port catheters (PORTs)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Peripherally inserted central catheters (PICCs)
Number of subjects: 256
Study: 29397092

Group type: EXPERIMENTAL
Intervention: Rhus capsules
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 27689547

Group type: EXPERIMENTAL
Intervention: Steroid + antiviral
Number of subjects: 50

Group type: COMPARATOR
Intervention: Steroid
Number of subjects: 50
Study: 24152667

Group type: EXPERIMENTAL
Intervention: Home-based case management intervention (monthly home visits by nurses and physiotherapists for 12 months)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Home-based case management intervention
Number of subjects: 153
Study: 22215470

Group type: EXPERIMENTAL
Intervention: Family-only intervention
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Community-only intervention
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Family + Community intervention
Number of subjects: 808

Group type: COMPARATOR
Intervention: Measurement-only condition
Number of subjects: 808
Study: 20481635

Group type: EXPERIMENTAL
Intervention: Nylon-3 copolymers with N-terminal octadecanoyl unit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nylon-3 copolymers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discrete peptides intended to mimic SP-B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peptoid-based mimic
Number of subjects: 0
Study: 18033323

Group type: EXPERIMENTAL
Intervention: Heterozygous for XRCC3 Thr241Met allele
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Etoposide, daunomycin (therapy likely to generate DNA double-strand breaks)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Anti-metabolite therapy (fludarabine, cytarabine)
Number of subjects: 452

Group type: COMPARATOR
Intervention: RAD51 G135C and GSTM1 deletion polymorphism
Number of subjects: 452
Study: 15830989

Group type: EXPERIMENTAL
Intervention: Autologous fat placement around the spinal root (group A)
Number of subjects: 74

Group type: COMPARATOR
Intervention: No autologous fat placement (control group B)
Number of subjects: 74
Study: 11828042

Group type: EXPERIMENTAL
Intervention: Patients with COPD
Number of subjects: 23

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 23
Study: 10426347

Group type: EXPERIMENTAL
Intervention: Cathodal configuration
Number of subjects: 200

Group type: COMPARATOR
Intervention: Anodal configuration
Number of subjects: 200
Study: 7731622

Group type: EXPERIMENTAL
Intervention: Morphine sulphate (i.v.)
Number of subjects: 60

Group type: COMPARATOR
Intervention: CCK (i.v.)
Number of subjects: 60
Study: 2103209

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Xipamide
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Patients with LVH
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Overall treatment effect
Number of subjects: 42
Study: 6116296

Group type: EXPERIMENTAL
Intervention: Ketotifen 1 mg bd for four weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ketotifen 1 mg, 2 mg, and 4 mg before exercise
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 30850941

Group type: EXPERIMENTAL
Intervention: Indicators of general health and economic deprivation
Number of subjects: 2501

Group type: EXPERIMENTAL
Intervention: Each degree of deprivation
Number of subjects: 2501

Group type: EXPERIMENTAL
Intervention: Households with two or more poverty indicators
Number of subjects: 2501
Study: 28567691

Group type: EXPERIMENTAL
Intervention: Adipose tissue-derived stem cells (ASCs) at a dose of 1 × 10^7 cells/mL
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Adipose tissue-derived stem cells (ASCs) at a dose of 2 × 10^7 cells/mL
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Adipose tissue-derived stem cells (ASCs)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 15
Study: 26579572

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg in the morning) and placebo (in the evening) for 24 weeks
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg in the morning) and melatonin (5 mg in the evening) for 24 weeks
Number of subjects: 64
Study: 23713815

Group type: EXPERIMENTAL
Intervention: Rate control strategy for treatment of AF
Number of subjects: 265

Group type: COMPARATOR
Intervention: Rhythm control strategy for treatment of AF
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Higher tertile MPV group (≥7.9 fL)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: MPV cut-off level set to 7.85 fL
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Rate control strategy with high MPV (>7.85 fL) and high CHADS2 score
Number of subjects: 265
Study: 21676011

Group type: COMPARATOR
Intervention: XEN-D0501 1 mg twice daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: XEN-D0501 2.5 mg twice daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: XEN-D0501 5 mg twice daily
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: XEN-D0501 5 mg single dose (fasted and fed conditions)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 19765496

Group type: EXPERIMENTAL
Intervention: Enhanced podcast (based on social cognitive theory)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control podcast
Number of subjects: 78
Study: 17205438

Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin (1 g)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 3-day azithromycin (500 mg daily)
Number of subjects: 156

Group type: COMPARATOR
Intervention: 3-day levofloxacin (500 mg daily)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Azithromycin-based regimens (single-dose and 3-day)
Number of subjects: 156
Study: 15601351

Group type: EXPERIMENTAL
Intervention: 0.1% bupivacaine + 5 microg x ml(‐1) fentanyl
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine + 5 microg x ml(‐1) fentanyl
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 31
Study: 11235719

Group type: EXPERIMENTAL
Intervention: Cardiac ischemic preconditioning (group IP): two cycles of 3 minutes of aortic cross‐clamping and 2 minutes of reperfusion before cardioplegic arrest
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (group C): 10 minutes of cardiopulmonary bypass
Number of subjects: 40
Study: 10986367

Group type: EXPERIMENTAL
Intervention: Meaningful labels (creative or non-creative)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meaningless labels (group 1 or group 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unlimited time to respond
Number of subjects: 0

Group type: COMPARATOR
Intervention: Forced to respond quickly
Number of subjects: 0
Study: 9127169

Group type: EXPERIMENTAL
Intervention: Octreotide, 40 micrograms/h, by continuous i.v. infusion for 5 days
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo in addition to standard supportive therapy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Octreotide group
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 58
Study: 1492864

Group type: EXPERIMENTAL
Intervention: 6-mg DHEC oral vial once daily for 3 months
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 6-mg DHEC tablet once daily for 3 months
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo vial once daily for 3 months
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo tablet once daily for 3 months
Number of subjects: 240
Study: 3891920

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen at a pressure of two atmospheres absolute
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 31228760

Group type: EXPERIMENTAL
Intervention: AFS (fentanyl bolus ± infusions)
Number of subjects: 90

Group type: COMPARATOR
Intervention: PDS (protocol-directed sedation)
Number of subjects: 90

Group type: COMPARATOR
Intervention: PDS + DSI (protocol-directed sedation + daily sedation interruption)
Number of subjects: 90
Study: 29197140

Group type: EXPERIMENTAL
Intervention: IFN+SOF+RBV for 12 weeks (n=155, genotypes 1 and 6)
Number of subjects: 686

Group type: COMPARATOR
Intervention: SOF+RBV for 12-24 weeks (n=531, all genotypes)
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Achieving SVR-12
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: IFN-free treatment
Number of subjects: 686
Study: 26192385

Group type: EXPERIMENTAL
Intervention: Family-based behavioral treatment (FBT) for obesity
Number of subjects: 148
Study: 24814566

Group type: EXPERIMENTAL
Intervention: Active tDCS stimulation over the right DLPFC at 2 mA for 30 min for five days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 21712301

Group type: EXPERIMENTAL
Intervention: Psychiatric label
Number of subjects: 322

Group type: COMPARATOR
Intervention: No psychiatric label (Control)
Number of subjects: 322
Study: 19788440

Group type: EXPERIMENTAL
Intervention: Sivelestat sodium hydrate (n=11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline (control group, n=11)
Number of subjects: 22
Study: 18591307

Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control (no Burch colposuspension)
Number of subjects: 322
Study: 16496603

Group type: EXPERIMENTAL
Intervention: Diabetic patients with autonomic neuropathy (DM-N(+))
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control patients on atropine (K-A)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Diabetic patients without autonomic neuropathy (DM-N(-))
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control patients on propranolol (K-P)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Non-diabetics after administration of atropine (K-A)
Number of subjects: 55
Study: 11932840

Group type: EXPERIMENTAL
Intervention: Group analysis of evaluations
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group analysis of evaluations (treatment questions)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group analysis of evaluations (differential diagnosis questions)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group analysis of evaluations (prognosis questions)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group training
Number of subjects: 100
Study: 10096582

Group type: EXPERIMENTAL
Intervention: Antiretroviral triple combination therapy (after 1996)
Number of subjects: 1027

Group type: COMPARATOR
Intervention: Antiretroviral triple combination therapy (before 1996)
Number of subjects: 1027
Study: 8562300

Group type: EXPERIMENTAL
Intervention: Nefazodone hydrochloride 200 mg twice daily for 6 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg four times daily for 6 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nefazodone hydrochloride 200 mg twice daily + Cimetidine 300 mg four times daily for 6 days
Number of subjects: 18
Study: 2147630

Group type: EXPERIMENTAL
Intervention: 4 injections regimen (basal-prandial with short-acting insulin before meals and isophane (NPH) insulin at bedtime)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 5 injections regimen (4 injections plus a second injection of isophane (NPH) insulin before breakfast)
Number of subjects: 43

Group type: COMPARATOR
Intervention: 4 injections regimen
Number of subjects: 43

Group type: COMPARATOR
Intervention: 5 injections regimen
Number of subjects: 43

Group type: COMPARATOR
Intervention: 4 injections regimen and 5 injections regimen
Number of subjects: 43
Study: 30948335

Group type: EXPERIMENTAL
Intervention: Functional p53 mutations
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Expression of p53, Δ40p53, and Δ133p53 isoforms in mutant (MT) p53 RCC
Number of subjects: 41

Group type: COMPARATOR
Intervention: Expression of Δ133p53 isoform in WT p53 tissues
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Overall survival in patients with functional p53 mutation
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Tumor stage and p53 mutation
Number of subjects: 41
Study: 28289894

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (gallium‐aluminum‐arsenide diode laser, 20 mW, applied in five doses)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (standard protocol for distalization)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 15
Study: 25879572

Group type: EXPERIMENTAL
Intervention: Psycho-education plus implementation intentions and mental imagery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psycho-education plus implementation intentions and mental imagery with text messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psycho-education control condition
Number of subjects: 0
Study: 22116961

Group type: EXPERIMENTAL
Intervention: TIMA protocol treatment by TIMA-trained psychiatrists over a 12-week period
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TIMA protocol treatment
Number of subjects: 40
Study: 21342376

Group type: EXPERIMENTAL
Intervention: Degarelix 80 mg monthly maintenance dose
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Degarelix 160 mg monthly maintenance dose
Number of subjects: 134

Group type: COMPARATOR
Intervention: Leuprolide 7.5 mg monthly
Number of subjects: 134
Study: 19247490

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) delivered on the parietal cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) delivered on the premotor cortex (PM)
Number of subjects: 0
Study: 17901084

Group type: EXPERIMENTAL
Intervention: Home-based self-sampling and testing
Number of subjects: 626

Group type: COMPARATOR
Intervention: Clinic-based testing
Number of subjects: 626
Study: 15654489

Group type: EXPERIMENTAL
Intervention: Bethanecol chloride tablets (20 mg, as needed)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11573633

Group type: EXPERIMENTAL
Intervention: Tegaderm dressing (group T)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Tegaderm dressing plus filter‐shoulder fixation (group F)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Niko Epi‐Fix dressing (group N)
Number of subjects: 111
Study: 9577354

Group type: EXPERIMENTAL
Intervention: Total Enteral Nutrition (TEN) for 7 days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN) for 7 days
Number of subjects: 34